Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease

NCT05007678 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

178

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: leflunomide

Sponsor

Ashford and St. Peter's Hospitals NHS Trust